Results 191 to 200 of about 2,156,550 (237)
Some of the next articles are maybe not open access.
Evaluation of anti‐thrombomodulin antibody as a tumor marker for vascular neoplasms
Journal of Cutaneous Pathology, 2004Background: Various endothelial markers are available for the evaluation of vascular tumors and malformations, including anti CD34, anti‐CD31, von Willebrand factor (vWF), and anti‐thrombomodulin (anti‐TM) antibodies. All have their limitations, and we sought to compare the utility of anti‐TM antibody as a marker for several types of vascular ...
Trey, Manning +6 more
openaire +2 more sources
Identification of T Lymphocytes in Ocular Adnexal Neoplasms by Hybridoma Monoclonal Antibodies
American Journal of Ophthalmology, 1983We performed indirect immunofluorescence with the OKT series of hybridoma monoclonal antibodies in order to determine the total number of T cells and their subset distribution, that is, the percentages of helper (OKT3+T4+T8-) and suppressor/cytotoxic (OKT3+T4-T8+) T cells, in 28 ocular adnexal lymphoid neoplasms.
D M, Knowles, F A, Jakobiec
openaire +2 more sources
Determination of proliferation index in neoplasms using different Ki‐67 equivalent antibodies
APMIS, 2003Paraffin sections from 23 tumours were immunohistochemically stained with the following four Ki‐67 equivalent antibodies: monoclonal MIB‐1 (DAKO), monoclonal MM1 (Novocastra), polyclonal NCL‐Ki‐67p (Novocastra), and polyclonal Rah Ki‐67 (DAKO). Ki‐67 labelling indices were determined by counting in exactly the same area in each case.
C F, Lindboe, G, von der Ohe, S H, Torp
openaire +2 more sources
Monoclonal antibody-based therapy of lymphoid neoplasms: What's on the horizon?
Seminars in Hematology, 2000Although exciting advances in monoclonal antibody therapy have already occurred, a review of agents in earlier stages of development reveals that many new agents may be approaching the clinic in the years to come. A look at the horizon of monoclonal antibody therapy reveals the following: novel strategies for augmenting the efficacy of monoclonal ...
openaire +2 more sources
Applied Immunohistochemistry & Molecular Morphology, 2002
DS6 is a murine monoclonal antibody that was developed using ovarian serous adenocarcinoma as immunogen. DS6 reacts immunohistochemically with a tumor-associated antigen, CA6, which has only a limited range of expression in normal human tissues. CA6 is most characteristically expressed in type II pneumocytes, fallopian tube epithelium, and urothelium ...
Nancy L, Smith +3 more
openaire +2 more sources
DS6 is a murine monoclonal antibody that was developed using ovarian serous adenocarcinoma as immunogen. DS6 reacts immunohistochemically with a tumor-associated antigen, CA6, which has only a limited range of expression in normal human tissues. CA6 is most characteristically expressed in type II pneumocytes, fallopian tube epithelium, and urothelium ...
Nancy L, Smith +3 more
openaire +2 more sources
11-Oxycorticosteroid-Dependent Antibody in the Serum of a Patient with Bladder Neoplasm
Vox Sanguinis, 1992AbstractAn IgM 11‐oxycorticosteroid‐dependent antibody was identified in the serum of a patient with bladder malignancy, which at 4–37°C reacted with all the 11‐oxycorticosteroids tested but not with desoxycorticosterone, testosterone, nortestosterone and progesterone. The resulting drug‐antidrug antibody complex combines nonspecifically with red blood
V, Pinto +4 more
openaire +2 more sources
Radioimmunodetection of gastrointestinal neoplasms with antibodies to carcinoembryonic antigen.
Cancer research, 1980Primary and secondary gastrointestinal tumors have been identified using sheep immunoglobulin G antibody to carcinoembryonic antigen radiolabeled with 131I. 99mTc-pertechnetate and 99mTc-human serum albumin were used to identify tissue spaces and blood pool and to facilitate external substraction imaging.
K R, Hine +4 more
openaire +1 more source
Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail
British Journal of Biomedical Science, 2002Incidence of malignant melanoma (MM) is rising rapidly throughout the Western world, and the number of melanocytic lesions removed for histological assessment has increased. MM can present with a myriad of histological appearances that make diagnosis problematic, particularly when dealing with metastatic deposits.
openaire +2 more sources
Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms
2015The antibody-drug conjugate (ADC) is a unique combination of potent cytotoxic drugs covalently linked to monoclonal antibodies (mAb) through a stable specialized chemical linker. Recombinant immunotoxins, fusion proteins which contain the cytotoxic portion of a protein toxin fused to the Fv portion of an antibody, represent the most promising group of ...
Tadeusz Robak, Pawel Robak
openaire +1 more source